Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Cost-effectiveness of prenatal screening strategies for congenital heart disease.

Pinto NM, Nelson R, Puchalski M, Metz TD, Smith KJ.

Ultrasound Obstet Gynecol. 2014 Jul;44(1):50-7. doi: 10.1002/uog.13287.

2.
3.

Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies.

Odibo AO, Coassolo KM, Stamilio DM, Ural SH, Macones GA.

Prenat Diagn. 2006 Jan;26(1):39-44.

PMID:
16378332
4.

Reducing the cost of detection of congenital heart disease in fetuses of women with pregestational diabetes mellitus.

Bernard LS, Ramos GA, Fines V, Hull AD.

Ultrasound Obstet Gynecol. 2009 Jun;33(6):676-82. doi: 10.1002/uog.6302.

5.

Influence of prenatal diagnosis on congenital heart defects.

DeVore GR.

Ann N Y Acad Sci. 1998 Jun 18;847:46-52.

PMID:
9668697
6.
7.

Prenatal screening for fetal aneuploidy in singleton pregnancies.

Chitayat D, Langlois S, Wilson RD; Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada; Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists.

J Obstet Gynaecol Can. 2011 Jul;33(7):736-50.

PMID:
21749752
8.

Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies.

Evans MI, Sonek JD, Hallahan TW, Krantz DA.

Ultrasound Obstet Gynecol. 2015 Jan;45(1):74-83. doi: 10.1002/uog.14693. Epub 2014 Dec 9.

9.

Fetal echocardiography at the time of the nuchal translucency scan.

Lombardi CM, Bellotti M, Fesslova V, Cappellini A.

Ultrasound Obstet Gynecol. 2007 Mar;29(3):249-57.

10.

[Ultrasound soft markers and fetal cardiac structural assessment at 11-14 weeks].

Yang Y, Zhang Y.

Zhonghua Fu Chan Ke Za Zhi. 2014 Mar;49(3):188-92. Chinese.

PMID:
24820303
11.

A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.

Odibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA.

Obstet Gynecol. 2005 Sep;106(3):562-8. Erratum in: Obstet Gynecol. 2006 Jan;107(1):209.

PMID:
16135588
12.

Prenatal detection of congenital heart disease in a low risk population undergoing first and second trimester screening.

Jørgensen DE, Vejlstrup N, Jørgensen C, Maroun LL, Steensberg J, Hessellund A, Jørgensen FS, Larsen T, Shalmi AC, Skibsted L, Zingenberg H, Ekelund C, Tabor A.

Prenat Diagn. 2015 Apr;35(4):325-30. doi: 10.1002/pd.4525. Epub 2015 Feb 16.

PMID:
25352400
13.

The cost effectiveness of prenatal ultrasound screening for trisomy 21.

Harris AH.

Int J Technol Assess Health Care. 2004 Fall;20(4):464-8.

PMID:
15609796
14.

Detection of congenital heart defects throughout pregnancy; impact of first trimester ultrasound screening for cardiac abnormalities.

Eleftheriades M, Tsapakis E, Sotiriadis A, Manolakos E, Hassiakos D, Botsis D.

J Matern Fetal Neonatal Med. 2012 Dec;25(12):2546-50. doi: 10.3109/14767058.2012.703716. Epub 2012 Jul 6.

PMID:
22712625
15.

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.

Jelliffe-Pawlowski LL, Walton-Haynes L, Currier RJ.

Am J Med Genet A. 2008 Oct 1;146A(19):2455-67. doi: 10.1002/ajmg.a.32513.

PMID:
18785270
16.

Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies.

Müller MA, Clur SA, Timmerman E, Bilardo CM.

Prenat Diagn. 2007 Feb;27(2):164-9.

PMID:
17238215
17.

Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.

Knowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C.

Health Technol Assess. 2005 Nov;9(44):1-152, iii-iv. Review.

18.

Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis.

Caughey AB, Kuppermann M, Norton ME, Washington AE.

Am J Obstet Gynecol. 2002 Nov;187(5):1239-45.

PMID:
12439512
19.

Improving the effectiveness of routine prenatal screening for major congenital heart defects.

Carvalho JS, Mavrides E, Shinebourne EA, Campbell S, Thilaganathan B.

Heart. 2002 Oct;88(4):387-91.

20.

The role of nuchal translucency in the screening for congenital heart defects.

Bruns RF, Moron AF, Murta CG, Gonçalves LF, Zamith MM.

Arq Bras Cardiol. 2006 Sep;87(3):307-14. English, Portuguese.

Supplemental Content

Support Center